Common stock, $.01 par value per share
- Symbol
- HAE
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Haemonetics Corporation
HAENYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2026 Results; →Company context
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Current securities
Registered securities in this filing
HAEMONETICS CORPORATION · 8-K · Filed 2026-02-05
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Filed exhibits (1)
Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2026 Results; Raises Total Company Fiscal 2026 Guidance Boston, MA, February 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its third quarter and year-to-date of fiscal 2026, which ended December 27, 2025: 3rd Quarter 2026 Year-to-Date 2026 ─────────────────────────────────────────────────────────────────────────────────────────────── n Revenue, decrease $339 million, (3)% $988 million, (4)% n Organic(1) revenue increase 1.2% —% n Organic ex-CSL(2) revenue increase 7.5% …
Open exhibit ↗